Branded generics are generic drugs that have been given a proprietary market name. They may be marketed similarly to how branded drugs are. Branded generic drugs attach proprietary names to generic drug molecules. Ordinary generic drugs are usually known by their chemical name.
TEVA PHARMACEUTICAL INDUSTRIES LTD. and Sandoz- Notable Market Players in Branded Generics Market
The branded generics’ market is majorly comprised of top players involving MYLAN N.V., TEVA PHARMACEUTICAL INDUSTRIES LTD., GlaxoSmithKline plc, Bausch Health (Valeant Pharmaceuticals), Sandoz International Gmbh, Aspen Holdings, Par Pharmaceuticals, Lupin, Sanofi, AstraZeneca, Dr. Reddy’s Laboratories Inc., and Hetero
The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the branded generics market:
| Year | News |
| March-2022 | Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of a first generic version of Revlimid 1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States. |
| January-2021 | Sandoz, a global leader in generic and biosimilar medicines, announced the US launching of generic Icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema (HAE) in adults 18 years and older.1 It is available immediately for US patients. |
